[Afro Chic] More than 80 leading academics, teachers and researchers have written to the President surrounding the need to make changes to South Africa’s patent law, particularly around issues pertaining to COVID-19. It details their urges to the President to engage in a process of law reform- something to which his offices have already committed, although progress in this regard has been slow. The letter relates to both existing and prospective patented and patentable equipment that may be used to combat or mitigate the effects of the pandemic and includes products such as respirators and personal protective equipment (PPE) as well as diagnostic testing equipment and medicines.

[Universities Allied for Essential Medicine Europe] Today, May 18th, Universities Allied for Essential Medicines (UAEM), in collaboration with multiple American medical student organizations, has launched an interactive mapping tool that highlights key research universities and institutions that are receiving taxpayer money to develop novel diagnostics, therapeutics, and/or vaccines for COVID-19. The tool powerfully demonstrates the indispensable role of universities, public research institutions and public funding in the development of novel medical technologies. By visualizing where public funding is being directed, this tool contributes to transparency regarding the current significant levels of public investment and aims to hold research universities and institutions accountable to their social responsibilities to the public by ensuring any resulting technologies will be affordable and accessible to all.

The deadly public policy of letting Big Pharma companies like Gilead control access to COVID-19 therapies is clearer now than ever before. While promising “global access” out of one side of its mouth, Gilead has shown its true intentions with new, confidential bilateral licenses negotiated with five generic companies in India and Pakistan. These licenses only cover approximately 52% of the global population leaving the other 48% of the whim of Gilead’s monopoly-based predations. These licenses exclude people living in at least 73 countries and territories, including, outrageously, 30 low- and middle-income countries. Gilead wants to exercise total monopoly control over manufacture and sale in those 73 countries, giving it unfettered freedom to charge prices far in excess of the estimated $5-$10 per treatment that it costs to manufacture remdesivir.

[Carlos M. Correa] Like other rights, patent rights are not absolute. There are situations in which their exercise can be limited to protect public interests. Such situations may arise, for instance, when access to needed pharmaceutical products must be ensured. Compulsory licenses and government use for non-commercial purposes are tools, provided for under most laws worldwide, that can specifically be used to address public health needs. This document is intended to provide legal guidance for the effective use of such tools, consistently with the international law.

...Access to affordable medicines, vaccines and diagnostics and to medical equipment, and to the technologies to produce them, is indispensable to treat COVID-19. Such technologies should be broadly available to manufacture and supply what is needed to address the disease... In this connection, I wish to recall that in accordance to the ‘Security Exceptions’ contained in Article 73(b) of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement), any World Trade Organization Member can take “any action which it considers necessary for the protection of its essential security interests”. The use of this exception will be fully justified to procure medical products and devices or to use the technologies to manufacture them as necessary to address the current health emergency.